首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Economics at the FTC: Drug and PBM Mergers and Drip Pricing
Authors:Howard A Shelanski  Joseph Farrell  Daniel Hanner  Christopher J Metcalf  Mary W Sullivan  Brett W Wendling
Institution:1. Federal Trade Commission, Bureau of Economics, 600 Pennsylvania Ave., N.W., Washington, DC, 20580, USA
2. Department of Economics, University of California, Berkeley, CA, 94720, USA
Abstract:Economists at the Federal Trade Commission pursue the agency??s competition and consumer protection missions. In this year??s essay, in antitrust, we discuss two recent mergers that involved Rx drugs: First, we describe key elements of the inquiry into the Express Scripts/Medco transaction in the pharmacy benefit management industry. Next, we analyze a merger that involved drugs that are used to treat patent ductus arteriosus: a condition that affects premature babies. On the consumer protection side, we discuss a pricing strategy??drip pricing??that involves the release of price information about a multi-part product over time as the consumer goes through the purchase process.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号